Fédération Hospitalo-Universitaire NEUROGENYCS Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT03910738
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fédération Hospitalo-Universitaire NEUROGENYCS

Active Ingredients

Drugs in Phase 2 Trials (1)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1